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Abstract
Objective: To assess whether eculizumab, a terminal complement inhibitor,
improves patient- and physician-reported outcomes (evaluated using the myas-
thenia gravis activities of daily living profile and the quantitative myasthenia
gravis scale, respectively) in patients with refractory anti-acetylcholine receptor
antibody-positive generalized myasthenia gravis across four domains, represent-
ing ocular, bulbar, respiratory, and limb/gross motor muscle groups. Methods:
Patients with refractory anti-acetylcholine receptor antibody-positive generalized
myasthenia gravis were randomized 1:1 to receive either placebo or eculizumab
during the REGAIN study (NCT01997229). Patients who completed REGAIN
were eligible to continue into the open-label extension trial (NCT02301624) for
up to 4 years. The four domain scores of each of the myasthenia gravis activities
of daily living profile and the quantitative myasthenia gravis scale recorded
throughout REGAIN and through 130 weeks of the open-label extension were
analyzed. Results: Of the 125 patients who participated in REGAIN, 117 enrolled
in the open-label extension; 61 had received placebo and 56 had received eculizu-
mab during REGAIN. Patients experienced rapid improvements in total scores
and all four domain scores of both the myasthenia gravis activities of daily living
profile and the quantitative myasthenia gravis scale with eculizumab treatment.
These improvements were sustained through 130 weeks of the open-label exten-
sion. Interpretation: Eculizumab treatment elicits rapid and sustained improve-
ments in muscle strength across ocular, bulbar, respiratory, and limb/gross motor
muscle groups and in associated daily activities in patients with refractory anti-
acetylcholine receptor antibody-positive generalized myasthenia gravis.
Introduction
Myasthenia gravis (MG) is a rare autoimmune disorder
characterized by fluctuating muscle weakness that carries
a heavy disease burden and impairs quality of life.1 MG is
mediated by autoantibodies that target the nicotinic
acetylcholine receptor (AChR) and activate the comple-
ment cascade in over 70% of patients, resulting in struc-
tural damage to the neuromuscular junction.2-7 This
impairs neuromuscular transmission and contributes to
muscle weakness, which eventually affects the face, neck,
hands, and/or limbs in 70–80% of patients with MG
(generalized MG [gMG]).8,9 MG is typically managed
with the use of immunosuppressive therapies (ISTs), but
10–15% of patients are considered to have refractory dis-
ease owing to intolerable IST-related adverse events,
inability to lower IST dose without clinical relapse, or
requirement for regular maintenance intravenous
immunoglobulin (IVIg) or plasma exchange treat-
ment.1,10-14 Persistent MG symptoms can adversely
impact breathing, talking, swallowing, walking, and other
activities requiring limb strength.15
Eculizumab (Soliris, Alexion Pharmaceuticals, Boston,
MA, USA) is a humanized monoclonal antibody that
binds with high affinity to the terminal complement pro-
tein C5. This inhibits enzymatic cleavage of C5 and pre-
vents downstream signaling of both C5a-induced
chemotaxis of proinflammatory cells and formation of the
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C5b-induced membrane attack complex,16 which is a pri-
mary driver of membrane damage at the neuromuscular
junction in anti-AChR antibody-positive (AChR+)
gMG.17,18
Eculizumab has been shown to be well tolerated and to
improve clinical outcomes in patients with refractory
AChR+ gMG in the 6-month, phase 3, randomized, dou-
ble-blind, placebo-controlled REGAIN study
(NCT01997229).15 Long-term tolerability and improve-
ments to clinical outcomes have also been shown in an
interim analysis of the REGAIN open-label extension
(OLE; NCT02301624).19
The MG activities of daily living profile (MG-ADL)20
and the quantitative MG scale (QMG)21 are validated,
MG-specific outcome measures, each of which comprise
four domains representing ocular, bulbar, respiratory, and
limb/gross motor muscle groups. The MG-ADL and
QMG were key, prospectively defined efficacy measures
used to assess patient outcomes in REGAIN and the OLE.
Both MG-ADL and QMG mean total scores improved
with eculizumab treatment during REGAIN and during
long-term follow-up in the OLE trial.15,19
The objective of this analysis was to evaluate the MG-
ADL and QMG domain scores for each muscle group in
patients during REGAIN and its OLE to determine
whether eculizumab is clinically beneficial across all mus-
cle groups in patients with refractory AChR+ gMG. Our
hypothesis was that eculizumab would elicit rapid and
sustained improvements across all MG-ADL and QMG
domains.
Methods
Study design and participants
REGAIN (NCT01997229) was a 6-month, phase 3, ran-
domized, double-blind, placebo-controlled study of eculi-
zumab in adults with refractory AChR+ gMG, for which
full methodology has been published previously.15
Briefly, eligible patients were 18 years of age or older,
had confirmed gMG with positive serology for AChR
autoantibodies, had an MG-ADL total score of 6 or
greater, and had received two or more ISTs, or at least
one IST with requirement for chronic IVIg or plasma
exchange therapy, in the preceding 12 months. Full eligi-
bility criteria have been published previously.15
Patients who chose to continue into the OLE
(NCT02301624) were required to enter it within 2 weeks
of completing REGAIN.19 All patients provided written,
informed consent. Written approval for the study proto-
col and all study amendments was obtained from inde-
pendent ethics committees or institutional review boards
at all participating sites.
Dosing
During REGAIN, participants were randomized to receive
intravenous eculizumab (maintenance dose, 1200mg every
2 weeks following a 4-week induction period) or matched
placebo for 26 weeks.15
During the OLE, after a 4-week blinded induction
phase, all participants received open-label eculizumab
1200 mg every 2 weeks for up to 4 years.19 Patients who
had received eculizumab during REGAIN constituted the
eculizumab/eculizumab group, and patients who had
received placebo during REGAIN constituted the placebo/
eculizumab group.
Assessments
The MG-ADL is a patient-reported, 8-item questionnaire
that reports on the functional impact of muscle weakness
on activities of daily living in patients with gMG. It com-
prises four domains, representing ocular (two items), bul-
bar (three items), respiratory (one item), and limb (two
items) muscle groups, which assess visual, oral, breathing,
and limb motor abilities, respectively.20 Each item is
scored from 0 to 3, with a maximum total score of 24.
The QMG is an objective, physician-reported, 13-item
measure of muscle strength that comprises four domains,
representing ocular (three ocular and facial muscle items),
bulbar (two swallowing and speech items), respiratory
(one forced vital capacity item), and gross motor (seven
limb and axial motor items) muscle groups.21 Each item
is scored from 0 to 3, with a maximum total score of 39.
The scores for all domains of the MG-ADL and QMG
were recorded throughout REGAIN and its OLE. Assess-
ments were performed weekly from week 1 to week 3 and
then at weeks 4, 8, 12, 16, 20, 26, 40, and 52 in year 1,
then every 6 months afterward and at each patient’s end-
of-study visit. The MG-ADL and QMG total and domain
scores from REGAIN and the completed OLE are
reported here.
Patients with an abnormal score (>0) at REGAIN base-
line for a domain of either measure were included in the
analysis of that domain for its respective measure. MG-
ADL and QMG mean total and mean domain scores were
calculated for both the eculizumab and the placebo
groups in the REGAIN study and for the eculizumab/ecu-
lizumab and placebo/eculizumab groups in the OLE.
Statistical analysis
Two baselines were used for these analyses; the REGAIN
baseline (REGAIN day 1) was used to allow for assess-
ment of response to eculizumab from the start of
REGAIN, and the open-label baseline (the last available
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assessment before the first eculizumab dose in the OLE)
was used to allow for assessment of response to eculizu-
mab in the placebo/eculizumab group and assessment of
maintenance of the response observed during REGAIN in
the eculizumab/eculizumab group.19 Changes from
REGAIN baseline to OLE week 130 (156 weeks, in total,
for patients who had received eculizumab during
REGAIN) and from open-label baseline to OLE week 130
were evaluated. In addition, for the correlation analysis,
eculizumab baseline was defined as the first dose of eculi-
zumab received.
Repeated-measures analyses for changes in MG-ADL
and QMG total and domain scores from open-label base-
line were performed. These data are presented as least-
squares means and 95% confidence intervals (CIs). Pear-
son’s correlation coefficients (R) by treatment group were
determined for MG-ADL and QMG total score changes
from eculizumab baseline to last OLE assessment and for
MG-ADL and QMG total scores at last OLE assessment;
thresholds for moderate and strong correlations were 0.4
and 0.6, respectively.22 All statistical analyses were per-
formed using SAS version 9.4 (SAS Institute, Cary, NC,




During REGAIN, 62 patients received eculizumab and 63
received placebo. Of the 118 patients who completed
REGAIN, 117 (eculizumab/eculizumab, 56; placebo/eculi-
zumab, 61) enrolled in the OLE (93.6% of REGAIN par-
ticipants [117/125] entered the OLE). Almost three-
quarters (74.4%) of OLE participants (87/117) completed
the OLE. Of the 30 patients who discontinued during the
OLE, seven discontinued due to adverse events, and there
were three deaths reported in patients with important
comorbidities19 (Fig. 1). The median duration of eculizu-
mab treatment during the OLE (from open-label baseline
to last OLE assessment) was 2.7 years (138.9 weeks;
range, 0.1–196.0 weeks). Full final safety data will be pub-
lished (Mantegazza R, et al. 2020. Minimal manifestations
in eculizumab-treated patients with refractory myasthenia
gravis. Manuscript submitted for publication).
All OLE participants had at least one abnormal domain
score for both MG-ADL and QMG at REGAIN baseline
and were, therefore, included in the analysis of total
scores. The numbers of patients in the eculizumab/eculi-
zumab and placebo/eculizumab groups, respectively, who
had abnormal REGAIN baseline scores and were included
in this analysis were: for the MG-ADL domains, 55 and
59 for ocular, 54 and 55 for bulbar, 48 and 45 for
respiratory, and 52 and 55 for limb; and for the QMG
domains, 56 and 60 for ocular, 31 and 28 for bulbar, 28
and 36 for respiratory, and 56 and 61 for gross motor.
MG-ADL and QMG mean total scores
For patients in the eculizumab/eculizumab group, the
improvements achieved in both MG-ADL and QMG
mean total scores during REGAIN15 and the interim anal-
ysis of OLE data19 were found to be sustained in this final
analysis of the complete OLE data through 130 weeks
(Figs. 2, 3).
Patients in the placebo/eculizumab group experienced
rapid improvements in MG-ADL and QMG mean total
scores from the start of eculizumab treatment in the OLE
during the 4-week blinded induction period (Figs. 2, 3).
In this group, MG-ADL and QMG mean total scores were
significantly improved from open-label baseline as early
as OLE week 1 (P ≤ 0.001), and these improvements
remained significant for every week through 130 weeks
(Fig. 3).
MG-ADL and QMG total score correlation
In the eculizumab/eculizumab group, there were strong
correlations between changes in MG-ADL and QMG total
scores from eculizumab baseline to last OLE assessment
(R = 0.73; 95% CI, 0.57–0.83; Fig. 4A) and between MG-
ADL and QMG total scores at last OLE assessment
(R = 0.69; 95% CI, 0.510.80; Fig. 4B).
In the placebo/eculizumab group, the correlations
between MG-ADL and QMG total scores were also strong
for changes in total scores from eculizumab baseline to
last OLE assessment (R = 0.74, 95% CI, 0.59–0.83;
Fig. 4A) and for total scores at last OLE assessment
(R = 0.77; 95% CI, 0.640.86; Fig. 4B).
For the entire OLE population, the coefficients for the
correlations between changes in MG-ADL and QMG total
scores from eculizumab baseline to last OLE assessment
and between the total scores at last OLE assessment were
0.74 (95% CI, 0.65–0.81) and 0.73 (95% CI, 0.63–0.80),
respectively.
MG-ADL domain scores
Patients in the eculizumab/eculizumab group experienced
rapid improvements across all four MG-ADL domains
during REGAIN, and this treatment effect was sustained
through 130 weeks of the OLE (Fig. 5A–D and Fig. 6A–
D). During REGAIN, peak improvements were observed
by week 16 in all domains except the respiratory domain,
in which it was observed by week 4 (Fig. 5A–D). There-
after, the peak improvements achieved in REGAIN were
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sustained or increased in all domains during the OLE
through 130 weeks (Fig. 6A–D).
In the placebo/eculizumab group, statistically significant
improvements in scores from open-label baseline were
observed in the ocular, bulbar, and limb domains as early
as week 1 and remained significant at each time point
through 130 weeks (Fig. 6A, B, D). In the respiratory
domain, the improvement in score was statistically signifi-
cant by week 4 and remained significant at each time
point through 130 weeks except at week 78 (Fig. 6C).
QMG domain scores
Patients in the eculizumab/eculizumab group experienced
rapid improvements across all four QMG domains during
REGAIN, and this treatment effect was sustained through
130 weeks of the OLE (Fig. 7A–D and Fig. 8A–D). Dur-
ing REGAIN, peak improvements were observed by week
26 in the ocular and gross motor domains (Fig. 7A, D),
week 20 in the bulbar domain (Fig. 7B), and week 12 in
the respiratory domain (Fig. 7C). Thereafter, the peak
improvements achieved in REGAIN were sustained or
increased in all domains during the OLE through
130 weeks, except in the bulbar domain at week 130
(Fig. 8A–D).
In the placebo/eculizumab group, statistically significant
improvements from open-label baseline were observed
across all domains by week 1, except for the bulbar
domain, which was first significantly improved at week 40
(Fig. 8A–D). In the ocular and gross motor domains,
improvements from open-label baseline were significant
for every week through 130 weeks (Fig. 8A, D). In the
bulbar and respiratory domains, improvements from
open-label baseline were significant at weeks 40, 52, 78,
and 104, and at weeks 1, 2, 3, 4, and 16, respectively
(Fig. 8B, C).
Discussion
Eculizumab is effective in the long-term treatment of
patients with refractory AChR+ gMG.19 In the REGAIN
OLE, rapid improvements in MG-ADL and QMG total
scores with eculizumab were observed to be sustained
through 156 weeks. Final OLE safety data were consistent
with interim OLE safety data and eculizumab’s known



















117 patients entered the open-label extension study
5 discontinued
• 4 adverse events
• 1 withdrawal 
 by patient
13 discontinued
• 2 adverse events
• 2 deaths
• 5 withdrawals 
 by patient
















• 2 withdrawals 
 by patient
17 discontinued
• 5 adverse events
• 1 death
• 8 withdrawals 
 by patient
• 3 withdrawals 
 by physician
Figure 1. Patient disposition through January 2019. In total, 117 patients were enrolled in the OLE; 56 had received eculizumab and 61 had
received placebo during REGAIN. At OLE study end, 30 patients in total had discontinued (23.2% of the eculizumab/eculizumab group [13/56]
and 27.9% of the placebo/eculizumab group [17/61]), and 87 patients had completed the study (76.8% of the eculizumab/eculizumab group
[43/56] and 72.1% of the placebo/eculizumab group [44/61]). OLE = open-label extension. Figure reproduced with permission from Vissing J,
Jacob S, Fujita KP, et al. ‘Minimal symptom expression’ in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia
gravis treated with eculizumab. J Neurol 2020. (https://creativecommons.org/licenses/by/4.0/).
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Minimal manifestations in eculizumab-treated patients
with refractory myasthenia gravis. Manuscript submitted
for publication).
We previously reported that the correlation between
MG-ADL and QMG total scores was stronger when
assessing response to treatment than baseline status23 and
that there was a strong correlation between scores after
26 weeks of eculizumab treatment.24 Correlation analysis
of the final OLE data confirms these observations for
long-term eculizumab treatment (median treatment dura-
tion was over 2.5 years). The strong correlations between
MG-ADL and QMG total scores, both for changes from
eculizumab baseline to last OLE assessment and at last
OLE assessment, demonstrate that the long-term effect of
eculizumab is consistent between the MG-ADL and QMG
assessments. This finding further validates use of the MG-
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Figure 2. Changes in (A) MG-ADL mean total score and (B) QMG mean total score from REGAIN baseline to OLE week 130. Patient numbers
were not the same for each assessment. BL = baseline; CI = confidence interval; MG-ADL = myasthenia gravis activities of daily living profile;
OLE = open-label extension; QMG = quantitative myasthenia gravis scale.
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ADL in assessing response to treatment in MG and pro-
vides evidence that patient-reported improvements in
response to long-term eculizumab treatment are sup-
ported by objective physician assessments of patients with
refractory AChR+ gMG.
At REGAIN baseline, all study participants had at least
one abnormal domain score for both MG-ADL and
QMG, and had experienced inadequate treatment
responses with standard ISTs. In contrast to other MG
therapies that have been reported to have differential
effects across muscle groups and onsets of action of up to
12 months,25,26 improvements were observed across the
MG-ADL domains for all four muscle groups within a
few weeks of eculizumab initiation and maintained
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Figure 3. Changes in (A) MG-ADL LS mean total score and (B) QMG LS mean total score from open-label baseline to week 130. ‡P ≤ 0.001
compared with open-label extension baseline, repeated-measures analysis. Patient numbers were not the same for each assessment. Stable scores
in the eculizumab/eculizumab group are evidence of maintained improvement achieved during eculizumab treatment in REGAIN in these patients.
BL = baseline; CI = confidence interval; LS = least-squares; MG-ADL = myasthenia gravis activities of daily living profile; QMG = quantitative
myasthenia gravis scale.
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through at least 130 weeks. This demonstrates that eculi-
zumab elicits rapid and sustained improvements in
patients’ breathing and functioning in a wide range of
activities of daily living. These patient-reported improve-
ments were supported by objective, physician-reported
improvements in muscle strength with eculizumab, as
evaluated by QMG domain scores across all four muscle
groups, which were also rapid and sustained through at
least 130 weeks. It remains a possibility that there is a
subset of patients who respond to eculizumab later than
what is observed in the study population as a whole; this



























































Change from eculizumab baseline in QMG at last assessment
QMG total score at last assessment
Correlation coefficient (R) = 0.73 for eculizumab/eculizumab
Correlation coefficient (R) = 0.74 for placebo/eculizumab
Correlation coefficient (R) = 0.69 for eculizumab/eculizumab
Correlation coefficient (R) = 0.77 for placebo/eculizumab









Figure 4. Correlations between MG-ADL and QMG total scores (A) for changes from eculizumab baseline to last OLE assessment and (B) at last
OLE assessment. Pearson’s correlation coefficients (R) were calculated for each treatment group. Each regression line was determined by a simple
linear regression model of (A) change in MG-ADL total score from REGAIN baseline to last OLE assessment against change in QMG total score
from eculizumab baseline to last OLE assessment or (B) MG-ADL total score at last OLE assessment as the response variable against QMG total
score at last OLE assessment as the predictor variable for respective treatment groups, and its 95% confidence band was determined by the
pointwise 95% confidence band. MG-ADL = myasthenia gravis activities of daily living profile; OLE = open-label extension; QMG = quantitative
myasthenia gravis scale.
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Figure 5. Changes in MG-ADL mean domain scores from REGAIN baseline to OLE week 130 for (A) ocular, (B) bulbar, (C) respiratory, and (D)
limb domains. Patient numbers were not the same for each assessment. Data are from patients with abnormal domain scores at REGAIN baseline
only. BL = baseline; CI = confidence interval; MG-ADL = myasthenia gravis activities of daily living profile; OLE = open-label extension.
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Figure 6. Changes in MG-ADL LS mean domain scores from open-label baseline to week 130 for (A) ocular, (B) bulbar, (C) respiratory, and (D)
limb domains. *P ≤ 0.05, †P ≤ 0.01, ‡P ≤ 0.001 compared with open-label baseline, repeated-measures analysis. Patient numbers were not the
same for each assessment. Stable scores in the eculizumab/eculizumab group are evidence of maintained improvement achieved during
eculizumab treatment in REGAIN in these patients. Data are from patients with abnormal domain scores at REGAIN baseline only. BL = baseline;
CI = confidence interval; LS = least-squares; MG-ADL = myasthenia gravis activities of daily living profile.
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Figure 7. Changes in QMG mean domain scores from REGAIN baseline to OLE week 130 for (A) ocular, (B) bulbar, (C) respiratory, and (D) gross
motor domains. Patient numbers were not the same for each assessment. Data are from patients with abnormal domain scores at REGAIN
baseline only. BL = baseline; CI = confidence interval; OLE = open-label extension; QMG = quantitative myasthenia gravis scale.
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Figure 8. Changes in QMG LS mean domain scores from open-label baseline to week 130 for (A) ocular, (B) bulbar, (C) respiratory, and (D)
gross motor domains. *P ≤ 0.05, †P ≤ 0.01, ‡P ≤ 0.001 compared with open-label baseline, repeated-measures analysis. Patient numbers were
not the same for each assessment. Stable scores in the eculizumab/eculizumab group are evidence of maintained improvement achieved during
eculizumab treatment in REGAIN in these patients. Data are from patients with abnormal domain scores at REGAIN baseline only. BL = baseline;
CI = confidence interval; LS = least-squares; QMG = quantitative myasthenia gravis scale.
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analysis (Howard J, et al. Long-term efficacy of eculizu-
mab in refractory generalized myasthenia gravis: respon-
der analyses. Manuscript in development).
It is notable that these improvements were achieved by
patients with refractory disease, a population with signifi-
cant disease burden,1 and that most participants com-
pleted the OLE. These data are important in the context
of clinical decision-making for patients with gMG, regard-
less of whether their symptoms are primarily driven by a
single domain (for example, ocular) or by multiple
domains. Eculizumab, therefore, alleviates a significant
and unmanaged disease burden across different muscle
groups that affect quality of life, confirming the efficacy
and value of inhibiting the C5 complement protein as a
therapeutic strategy for patients with refractory
AChR+ gMG.
The OLE of REGAIN allowed all patients who com-
pleted REGAIN to receive long-term eculizumab treatment
and, thus, yielded long-term data on its safety and effec-
tiveness. Limitations of the REGAIN study and its OLE
have been discussed previously.15,19 The open-label design
of the OLE component of this study is its main limitation,
which is a potential source of bias in reporting from both
patients and physicians. There were no substantial
changes, however, in MG-ADL and QMG total or domain
scores in the eculizumab/eculizumab group from the
open-label baseline, suggesting that any potential open-
label reporting bias was inconsequential in this analysis. In
addition, the blinded induction phase at the start of the
OLE confirmed the rapid treatment effect of eculizumab
in patients who had received placebo during REGAIN.
In summary, the results reported here confirm previous
REGAIN and interim OLE data showing that eculizumab
treatment results in rapid improvements in MG-ADL and
QMG total scores that are sustained through at least
130 weeks in individuals with refractory AChR+ gMG.19
Furthermore, the current analysis demonstrates that the
rapid and sustained effects of eculizumab in this patient
population are evident across the different MG-ADL and
QMG domains representing ocular, respiratory, bulbar,
and limb/gross motor muscle groups. It also demonstrates
consistency between patient and physician evaluations.
Eculizumab treatment, therefore, rapidly induces clinical
benefits across muscle groups, from both patient and
physician perspectives, which are maintained in the long
term in individuals with refractory AChR+ gMG.
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